The estimated Net Worth of Heather Preston is at least 2 百万$ dollars as of 4 September 2020. Heather Preston owns over 350 units of Karuna Therapeutics Inc stock worth over 1,913,014$ and over the last 9 years he sold KRTX stock worth over 0$. In addition, he makes 82,932$ as Independent Director at Karuna Therapeutics Inc.
Sign up
Heather Preston KRTX stock SEC Form 4 insiders trading
Heather has made over 7 trades of the Karuna Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 350 units of KRTX stock worth 25,326$ on 4 September 2020.
The largest trade he's ever made was buying 337,724 units of Karuna Therapeutics Inc stock on 28 September 2018 worth over 5,065,860$. On average, Heather trades about 20,110 units every 22 days since 2015. As of 4 September 2020 he still owns at least 5,800 units of Karuna Therapeutics Inc stock.
You can see the complete history of Heather Preston stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Heather Preston biography
Dr. Heather Preston M.D. serves as Independent Director of the Company. Dr. Preston has been the Managing Partner of Pivotal bioVenture Partners since July 2018, and previously she was a Firm Partner and Managing Director of TPG Biotech, a biotechnology venture capital firm, from May 2005 to July 2018. Prior to joining TPG Biotech, Dr. Preston was a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, and an Entrepreneur-in-Residence at New Enterprise Associates, a diversified venture capital firm. Before her investing career, she spent five years as a leader of the healthcare practice at Mckinsey & Co., advising large pharmaceutical and biotechnology companies on strategic issues. Dr. Preston holds a B.Sc.Hons degree in biochemistry from the University of London and an M.B.B.Chir degree in medicine from the University of Oxford. After leaving Oxford, Dr. Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Dr. Preston is trained in Internal Medicine at the Massachusetts General Hospital and then sub-specialized in Gastroenterology and Hepatology at U.C.S.F. She currently serves on the boards of directors of Otonomy, Inc., Oxford BioMedica plc and Entasis Therapeutics Holdings Inc., previously served on the board of directors of Alder Biopharmaceuticals Inc. and Albireo Pharma, Inc. and currently serves on the boards of directors of a number of private companies. Our board of directors believes that Dr. Preston is qualified to serve on our board of directors due to her experience working with and serving on the boards of directors of life sciences companies and her experience working in the venture capital industry.
What is the salary of Heather Preston?
As the Independent Director of Karuna Therapeutics Inc, the total compensation of Heather Preston at Karuna Therapeutics Inc is 82,932$. There are 12 executives at Karuna Therapeutics Inc getting paid more, with Steven Paul having the highest compensation of 10,050,700$.
How old is Heather Preston?
Heather Preston is 54, he's been the Independent Director of Karuna Therapeutics Inc since 2019. There are 11 older and 4 younger executives at Karuna Therapeutics Inc. The oldest executive at Karuna Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the CEO, Pres & Chairman.
What's Heather Preston's mailing address?
Heather's mailing address filed with the SEC is C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Karuna Therapeutics Inc
Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over 496,938,545$ worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth 53,814,390$ . The most active insiders traders include Health Llc Pure Tech、James Healy、Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of 18,341,187$. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth 636,600$.
What does Karuna Therapeutics Inc do?
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
What does Karuna Therapeutics Inc's logo look like?
Complete history of Heather Preston stock trades at Albireo Pharma Inc、Otonomy Inc、Entasis Therapeutics Inc、Karuna Therapeutics Inc、Akouos、Fusion Pharmaceuticals、Aligos Therapeutics
Karuna Therapeutics Inc executives and stock owners
Karuna Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Steven Paul,
Chairman of the Board, President, Chief Executive Officer -
Andrew Miller,
Chief Operating Officer -
Edmund Harrigan,
Independent Director -
Troy Ignelzi,
Chief Financial Officer -
Dr. Steven M. Paul M.D.,
CEO, Pres & Chairman -
Dr. Andrew Craig Miller,
Co-Founder & COO -
Dr. Stephen K. Brannan,
Chief Medical Officer -
Dr. Troy A. Ignelzi,
CFO & Sec. -
Stephen Brannan,
Chief Medical Officer -
Atul Pande,
Independent Director -
James Healy,
Independent Director -
Jeffrey Jonas,
Director -
Heather Preston,
Independent Director -
Robert Nelsen,
Independent Director -
Christopher Coughlin,
Independent Director -
Laurie Olson,
Director -
Giorgio Attardo,
Vice President, CMC and Preclinical Development -
Dr. Ronald N. Marcus M.D.,
Sr. VP of Medical -
Charmaine Lykins,
Chief Commercial Officer -
Dr. James E. Audia Ph.D.,
Head of Medicinal Chemistry & Sr. Adviser -
Dr. Alan Breier,
Chair of Scientific Advisory Board & Chief Clinical Advisor -
Stephanie Moore,
VP of HR -
Sharon Sawchak R.N.,
VP of Clinical Operations & Compliance -
Mia Kelley J.D.,
VP of Legal Affairs -
Jason Parker Brown,
VP of Corp. Fin. -
Venture Partners Ix, Llcarc...,
-
William Meury,
President and CEO -
Bharat M Chowrira,
Director -
Venture Partners Ix, Llcarc...,
-
Charmaine Lykins,
Chief Commercial Officer -
Health Llc Pure Tech,
-
David E. Wheadon,
-
Denice Torres,
-
William P Jr Kane,
Chief Commercial Officer -
Jason Parker Brown,
Chief Financial Officer